Starbucks
SBUX
$106.60
-0.20%
Starbucks Corp is the world's largest and most recognizable coffeehouse chain, operating nearly 41,000 company-operated and licensed stores across over 80 countries, with a business model centered on premium beverages, food, and consumer packaged goods. The company is a dominant market leader in the global coffee shop industry, distinguished by its powerful brand, extensive global footprint, and a highly customizable product platform. The current investor narrative is intensely focused on the company's ongoing turnaround strategy under CEO Brian Niccol, with recent headlines highlighting early signs of sales and profit growth, strategic cost-cutting measures including corporate layoffs, and a significant stock rally as the market assesses the durability of this operational recovery.…
SBUX
Starbucks
$106.60
Related headlines
Investment Opinion: Should I buy SBUX Today?
Rating: Hold. The core thesis is that SBUX is a high-risk, high-reward turnaround story where the current premium valuation fully prices in a successful recovery, leaving asymmetric downside risk if execution falters.
The Hold rating is supported by conflicting data points: strong technical momentum (25.99% 6-month gain) and robust free cash flow ($2.34B TTM) argue for patience, while severe margin compression (15.63% gross margin) and an elevated trailing P/E of 52.58x argue against new purchases. The forward P/E of 35.29x implies analysts expect significant earnings improvement, but the wide range of FY2026 EPS estimates ($3.98 to $4.62) underscores high uncertainty. The stock trades at 98% of its 52-week high, suggesting limited near-term upside without a major catalyst.
The thesis would upgrade to Buy if gross margins demonstrate a clear, sequential recovery back above 20% or if the forward P/E compresses below 25x on sustained earnings growth. It would downgrade to Sell if QoQ revenue growth decelerates further below 5% or if net margins fail to improve from the current TTM level of 4.99%. Based on the current data, the stock is overvalued relative to its near-term fundamentals but fairly valued relative to the long-term recovery narrative being priced in.
Sign up to view all
SBUX 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The investment is a binary bet on margin recovery, with the current price offering an unfavorable risk/reward skew. The strong cash flow and powerful brand provide a floor, but the extreme valuation and poor recent profitability cap the ceiling. The stance would upgrade to bullish only upon seeing two consecutive quarters of gross margin expansion. It would turn bearish if the next quarterly report shows further margin deterioration or a guidance cut, likely triggering a swift de-rating.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Starbucks's 12-month outlook, with a consensus price target around $138.58 and implied upside of +30.0% versus the current price.
Average Target
$138.58
12 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
12
covering this stock
Price Range
$85 - $139
Analyst target range
The stock is covered by 20 analysts, indicating robust institutional interest. While a specific consensus recommendation and average target price are not provided in the data, recent institutional rating actions show a mix of bullish and neutral stances, with firms like Barclays, Piper Sandler, and Wolfe Research maintaining 'Overweight' or 'Outperform' ratings, while others like RBC Capital, Guggenheim, and Citigroup hold 'Neutral' or 'Sector Perform' views, suggesting a cautiously optimistic but not uniformly bullish consensus. The range of analyst estimates is wide, with FY2026 revenue estimates spanning from $41.43 billion to $46.49 billion and EPS estimates from $3.98 to $4.62; this broad dispersion signals high uncertainty among analysts regarding the pace and magnitude of the company's recovery, with the high-end targets likely assuming successful margin expansion and market share gains, while the low-end targets may be pricing in continued cost pressures or competitive challenges.
Bulls vs Bears: SBUX Investment Factors
The bull and bear cases for SBUX are in a tense standoff, with the bear side currently holding stronger fundamental evidence. The severe margin collapse and premium valuation present concrete, near-term risks that outweigh the promising but unproven turnaround narrative. The single most important tension in the investment debate is whether CEO Brian Niccol's cost-cutting and strategic initiatives can restore gross margins to historical levels above 24% before valuation multiples contract. If margins recover as projected by the forward P/E of 35x, the bull case prevails; if cost pressures persist, the high multiple will unravel, validating the bear case.
Bullish
- Strong Turnaround Momentum: The stock has surged 25.99% over the past six months and 13.89% over the past three months, significantly outperforming the S&P 500. This technical strength is supported by recent news of a strong earnings beat and a raised outlook, confirming the market's belief in CEO Brian Niccol's strategy.
- Robust Free Cash Flow Generation: Despite profitability pressures, the company generated $2.34 billion in free cash flow over the trailing twelve months and $1.60 billion in operating cash flow last quarter. This provides ample internal resources to fund its turnaround, pay dividends, and navigate its leveraged balance sheet without immediate liquidity crisis.
- Analyst Support for Recovery: Several major institutions, including Barclays and Wolfe Research, maintain 'Overweight' or 'Outperform' ratings. The high-end FY2026 EPS estimate of $4.62 implies significant earnings recovery from the current depressed level of $0.26 in Q1, reflecting optimism for the turnaround plan.
- Dominant Global Brand & Scale: With nearly 41,000 stores across 80+ countries and a market cap of $110.8 billion, Starbucks possesses unparalleled scale and brand recognition. This provides a durable competitive moat and a massive platform from which to execute its operational recovery.
Bearish
- Severe Margin Compression: Gross margin collapsed to 15.63% in Q1 FY2026 from 24.49% a year ago, and net income fell to $293M from $781M. This indicates severe pressure from inflation and strategic costs, directly challenging the core profitability thesis of the turnaround.
- Extremely High Valuation: The stock trades at a trailing P/E of 52.58x and a forward P/E of 35.29x, which is historically high for a mature restaurant stock. This premium valuation leaves no room for error and is vulnerable to compression if earnings recovery falters.
- Weak Balance Sheet & Liquidity: The company has a negative debt-to-equity ratio of -3.29 and a weak current ratio of 0.72, signaling financial strain and potential liquidity concerns. This limits financial flexibility and increases risk if the turnaround takes longer than expected.
- Revenue Growth Deceleration: Q1 FY2026 revenue growth slowed to 5.43% YoY, down from higher rates in prior quarters. This deceleration, amidst the turnaround effort, raises questions about the company's ability to re-accelerate top-line growth in a competitive market.
SBUX Technical Analysis
The stock is in a sustained uptrend, evidenced by a 22.41% gain over the past year and a more pronounced 25.99% surge over the last six months. Currently trading at $106.82, the price sits at approximately 98% of its 52-week high of $108.88, indicating the stock is near its peak and testing a major resistance level, which suggests strong momentum but also potential for overextension. Recent momentum is exceptionally strong, with the stock up 8.62% over the past month and 13.89% over the past three months, significantly outpacing the S&P 500's gains of 5.6% and 8.42% over the same periods, respectively; this acceleration confirms the longer-term bullish trend and highlights the stock's recent outperformance. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $108.88 and support at the 52-week low of $77.99; a decisive breakout above resistance would signal a continuation of the powerful uptrend, while a failure could lead to a consolidation phase. With a beta of 1.009, the stock exhibits market-average volatility, but its recent price action and a high short ratio of 5.92 suggest it is experiencing elevated speculative interest and potential for sharp moves based on turnaround news flow.
Beta
1.01
1.01x market volatility
Max Drawdown
-19.1%
Largest decline past year
52-Week Range
$78-$109
Price range past year
Annual Return
+24.6%
Cumulative gain past year
| Period | SBUX Return | S&P 500 |
|---|---|---|
| 1m | +6.6% | +4.0% |
| 3m | +11.8% | +8.2% |
| 6m | +27.4% | +11.5% |
| 1y | +24.6% | +24.3% |
| ytd | +27.0% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SBUX Fundamental Analysis
Revenue growth has been positive but shows signs of deceleration and volatility; the most recent Q1 FY2026 revenue was $9.91 billion, representing a 5.43% year-over-year increase, yet this marks a slowdown from the 8-10%+ growth rates seen in prior quarters of FY2024, with the Beverage Member segment contributing $5.94 billion as the primary driver. Profitability is under significant pressure, with net income for Q1 FY2026 at $293 million, a sharp decline from $781 million in the year-ago quarter, and gross margin collapsing to 15.63% from 24.49% a year prior, indicating severe margin compression likely from inflationary costs and strategic investments; the trailing twelve-month net margin stands at 4.99%, reflecting this profitability challenge. The balance sheet shows financial strain with a negative debt-to-equity ratio of -3.29 and a weak current ratio of 0.72, signaling potential liquidity concerns; however, the company continues to generate substantial cash, with free cash flow over the trailing twelve months at $2.34 billion and an operating cash flow of $1.60 billion in the latest quarter, providing it with internal resources to fund its turnaround despite the leveraged balance sheet.
Quarterly Revenue
$9.9B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.15%
Latest Quarter
Free Cash Flow
$2.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SBUX Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 52.58x, while the forward PE is 35.29x, indicating the market is pricing in a significant recovery in earnings over the next year, with the gap between the two reflecting expectations for improved profitability. Compared to sector averages (data not provided in the input), a precise peer comparison cannot be quantified, but a trailing PE of 52.58x is historically high for a mature restaurant company, suggesting the market is awarding a premium for the perceived success of the turnaround narrative. Historically, the stock's own trailing PE has fluctuated widely, from lows around 20x in mid-2024 to recent highs above 80x in late 2025; the current 52.58x is above the mid-point of this range, indicating the stock is trading at a premium to its own history, which prices in optimistic expectations for margin recovery and growth re-acceleration, leaving little room for execution missteps.
PE
52.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 18x~184x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute. The company's profitability is under severe pressure, with Q1 gross margin collapsing by 880 basis points year-over-year to 15.63%. This margin compression, if sustained, directly threatens the earnings recovery priced into the stock's 35x forward P/E. The balance sheet shows significant strain with a negative debt-to-equity ratio of -3.29 and a current ratio of 0.72, indicating potential liquidity constraints despite strong cash flow. Revenue growth deceleration to 5.43% YoY adds another layer of operational risk, suggesting the turnaround is not yet driving robust top-line acceleration.
Market & Competitive Risks center on valuation compression. Trading at a trailing P/E of 52.58x—a premium to its own historical range—the stock is priced for a flawless execution of the turnaround. Any stumble in quarterly earnings or guidance could trigger a rapid de-rating. With a beta of 1.009, the stock has market-average volatility, but a high short ratio of 5.92 indicates elevated speculative interest and potential for sharp downside moves on negative news. The competitive landscape remains intense, with pressure from both high-end coffee shops and value-oriented chains, potentially capping pricing power needed for margin recovery.
Worst-Case Scenario involves a failure of the turnaround strategy to arrest margin decline, coupled with a growth slowdown. This could lead to consecutive earnings misses, analyst downgrades, and a full valuation compression towards the stock's 52-week low of $77.99. A re-rating to a more typical mature restaurant P/E in the low 20s on stagnant earnings would imply significant downside. From the current price of $106.82, a fall to the 52-week low represents a potential loss of approximately -27%. A more severe bear case, incorporating further earnings deterioration, could see losses exceeding 35%.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Severe margin compression, with Q1 gross margin at 15.63% down from 24.49%, threatening profitability and the valuation thesis. 2) Valuation Risk: A high trailing P/E of 52.58x leaves the stock vulnerable to multiple compression if earnings disappoint. 3) Operational Risk: Revenue growth deceleration to 5.43% YoY indicates challenges in re-accelerating the top line. 4) Balance Sheet Risk: A negative debt-to-equity ratio (-3.29) and weak current ratio (0.72) indicate financial strain despite strong cash flow.
The 12-month forecast is highly bifurcated, with three distinct scenarios. The Base Case (50% probability) sees the stock trading between $100 and $112 as the turnaround slowly progresses. The Bull Case (30% probability) projects a breakout to $115-$125 on successful margin recovery and re-accelerated growth. The Bear Case (20% probability) warns of a decline to $78-$95 if profitability fails to improve. The Base Case is most likely, predicated on the assumption that management's cost initiatives will gradually restore margins without a major macroeconomic setback. The wide analyst EPS estimate range for FY2026 ($3.98 to $4.62) underscores this high degree of forecast uncertainty.
SBUX is overvalued based on its current fundamentals but may be fairly valued if the turnaround succeeds. The trailing P/E of 52.58x is historically high for the company and the restaurant sector, especially when net income fell 62% year-over-year last quarter. The forward P/E of 35.29x shows the market is pricing in a substantial earnings recovery. Compared to its own history, where the P/E has fluctuated from ~20x to over 80x, the current multiple is above the midpoint, suggesting the market is paying a premium for hoped-for future profits. This valuation implies the market expects a near-complete restoration of pre-crisis margins and growth.
SBUX is not a good buy for conservative investors at its current price. The stock trades at a premium trailing P/E of 52.58x despite severe margin pressure, implying significant execution risk. For investors with a high-risk tolerance and a long-term horizon who believe firmly in the CEO's turnaround plan, it could be a speculative buy on any meaningful pullback. The average analyst target price is not provided, but the wide EPS estimate range ($3.98-$4.62) reflects high uncertainty. The most significant downside risk is a failure to restore profitability, which could lead to a -27% drop to the 52-week low of $77.99.
SBUX is unsuitable for short-term trading due to its binary turnaround narrative and high volatility risk (beta 1.009, high short interest). It is only appropriate for long-term investors with a minimum 2-3 year horizon who can weather potential drawdowns while awaiting the full effect of the strategic overhaul. The company pays a dividend (yield ~2.84%), which provides some income support for patient holders. Given the operational challenges and premium valuation, investors should be prepared for a holding period that spans multiple earnings cycles to validate or invalidate the recovery thesis.
